Pancreatic cancer

Advanced pancreatic carcinoma (APC) has a poor prognosis and chemotherapy remains the most common approach. Gemcitabine was the only drug recently approved for use as single agent therapy in APC. However, the combination of oxaliplatin and 5-fluorouracil (5-FU) has shown some promising results. This phase II trial was conducted to investigate the efficacy of oxaliplatin, 5-FU, and folinic acid (FOLFOX-6) in previously untreated APC patients. METHODS: We studied response rate, time to progression…

Eribulin mesylate (Halaven, Eisai), an FDA approved drug for use in late stage breast cancer is now concurrently indicated for the treatment of soft-tissue sarcoma (STS) that is inoperable or has metastasized known as liposarcoma. Eribulin mesylate can now be used in patients who have previously received anthracycline chemotherapy as treatment for liposarcoma. Liposarcoma is difficult to treat; most patients tend to have resection of malignant cells or curative surgery. Tumor cells are removed…

edu/Encyclopedia/Content.aspx?ContentTypeID=85&ContentID=P00965). Screening has been implemented for several cancers in the United States over the past few decades. For example, the colonoscopy for colorectal cancer and the mammogram for breast cancer. There is some controversy if the said screenings are responsible for the resulting decline in deaths from these specific cancers. Many cancers, including pancreatic cancer, have a better survival rate when able to be detected early (Poruk, Firpo,…

Targeted Cancer Therapy Since researchers learn about some of the differences that help cancer cells grow and thrive, it led them to “target” these differences through the development of drugs. Targeted therapy is basically a cancer treatment that uses medical drugs in curing the patient (medical drugs such as: Imatinib (Gleevec), Gefitinib (used in certain lung cancers), and Erlotinib (usually used pancreatic cancer). Clinical trials are performed in order to see whether targeted cancer therapy…

Pancreatic adenosquamous carcinoma (ASC) is a rare and aggressive tumor that has worse prognosis and higher metastatic potential than pancreatic adenocarcinoma(Kardon, Thompson et al. 2001, Boyd, Benarroch-Gampel et al. 2012). A major hindrance towards development of therapies against pancreatic ASC is that no unique molecular signature has been identified for this class of pancreatic tumors. Although KRAS and TP53 are altered in pancreatic ASC (Brody, Costantino et al. 2009), the same genes are…

Glimelius B et all conducted a randomized, controlled clinical trial, (62) between 1991 and 1995, on patients with pancreatic and biliary cancer to estimate any gain in the quantity and quality of life produced by chemotherapy. 90 eligible patients below the age of 76 years with surgically non-curable pancreatic or biliary adenocarcinoma were randomized into two groups: immediate chemotherapy along with best supportive care or to best supportive care only. If the supportive measures did not lead…

could thymoquinone become the cure to cancer? Thymoquinone has a similar chemical make to glucose and cellulose. Its chemical makeup is C10H12O2.…

The Connection Between Overeating and Cancer Food and nutrients are a necessity to live and thrive. However, consuming too much for this necessity can initiate a deadly chain reaction. Obesity is a disease stemming from various influences, such as the variety of food consumed and socioeconomic influences, but an important influence of this epidemic is overeating.9-12 Additionally, obesity is an epidemic impacting nearly 2 in 3 people within the United State population.1,2 Obesity as a disease…

suggest that consuming kaempferol may reduce the risk of various cancers, and it is currently under consideration as a possible cancer treatment. Epidemiological studies have revealed Kaempferol as a natural polyphenol belonging to the group of flavonoids. Epidemiological studies have found a positive association between the consumption of foods containing Kaempferol and a reduced risk of developing several disorders such as cancer and cardiovascular diseases. Insilico anticancer study of…

Ever since the discovery of recurrent gene fusions in prostate cancer in 20053, several prostate cancer specific molecular aberrations have been identified and are potentially targetable with specific inhibitors (Figure 1). Despite the high prevalence, the clinical utility and association of these markers with disease progression has not been firmly established. It may be due to the fact that the estimates on the prevalence of these molecular markers and clinical correlation analyses were based…